Treatment of type 2 diabetes patients with heart conditions

Basit Öğe Kaydı
dc.authorid0000-0001-7306-5233en_US
dc.authorid0000-0003-4201-9757en_US
dc.authorid0000-0001-7521-4060en_US
dc.authorid0000-0003-3651-4858en_US
dc.contributor.authorAktaş, Gülali
dc.contributor.authorTel, Burçin Meryem Atak
dc.contributor.authorTel, Ramiz
dc.contributor.authorBalcı, Buse
dc.date.accessioned2023-09-29T12:21:11Z
dc.date.available2023-09-29T12:21:11Z
dc.date.issued2023en_US
dc.departmentBAİBÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.description.abstractIntroductionWhile type 2 diabetes mellitus (T2DM) increases the risk of cardiac complications, diabetes treatment choices may increase or decrease the rates of cardiac events. In the present review, we comprehensively discussed the treatment options of diabetic subjects with cardiac conditions.Areas coveredCurrent evidence related to diabetes treatment in cardiac situations has been reviewed. Clinical trials and meta-analyses on cardiac safety of anti-diabetic medicines are discussed. Treatment choices with proven benefits and those at least without associated increased cardiac risk were drawn from clinical trials; meta-analyses and cardiac safety studies in the recent medical literature were the basis of the suggestions in the present review.Expert opinionWe can suggest that hypoglycemia and extreme hyperglycemia should be avoided in acute ischemic heart conditions. Certain diabetic treatment options, especially sodium-glucose cotransporter-2 (SGLT2) inhibitors, can reduce overall cardiovascular mortality and hospitalization due to heart failure. Therefore, we suggest that physicians should choose SGLT2 inhibitors as the first-line treatment option in diabetic patients with heart failure or those who have a high risk of heart failure development. T2DM increases the risk of atrial fibrillation (AF), and metformin and pioglitazone seem to reduce the risk of AF in diabetic population.en_US
dc.identifier.citationAktas, G., Atak Tel, B. M., Tel, R., & Balci, B. (2023). Treatment of type 2 diabetes patients with heart conditions. Expert Review of Endocrinology & Metabolism, 18(3), 255-265.en_US
dc.identifier.doi10.1080/17446651.2023.2204941
dc.identifier.endpage265en_US
dc.identifier.issn1744-6651
dc.identifier.issn1744-8417
dc.identifier.issue3en_US
dc.identifier.pmid37078758en_US
dc.identifier.scopus2-s2.0-85153477411en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage255en_US
dc.identifier.urihttp://dx.doi.org/10.1080/17446651.2023.2204941
dc.identifier.urihttps://hdl.handle.net/20.500.12491/11777
dc.identifier.volume18en_US
dc.identifier.wosWOS:000971482200001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorAktaş, Gülali
dc.institutionauthorTel, Burçin Meryem Atak
dc.institutionauthorBalcı, Buse
dc.language.isoenen_US
dc.publisherROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTDen_US
dc.relation.ispartofExpert Review of Endocrinology & Metabolismen_US
dc.relation.publicationcategoryDiğeren_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectType 2 Diabetes Mellitusen_US
dc.subjectCardiac Conditionsen_US
dc.subjectHeart Failureen_US
dc.subjectAtrial Fibrillationen_US
dc.subjectDiabetes Treatmenten_US
dc.titleTreatment of type 2 diabetes patients with heart conditionsen_US
dc.typeReview Articleen_US

Dosyalar

Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Dahili Tıp Bilimleri Bölümü Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu